Vglycin
Peptide Power for a Balanced Sweet Life
Your Key to Glycemic Harmony
l
o
a
d
i
n
g
In order to better browse the web, it is recommended to use a computer to watch.
Peptide Power for a Balanced Sweet Life
Your Key to Glycemic Harmony
Discover how Vglycin can revolutionize the treatment of Type 2 diabetes.
Diabetes is a chronic non-communicable lifelong disease that threatens the health of people around the world. Type 2 diabetes (T2D) accounts for over 90% of the cases. The main clinical manifestation of T2D characterizes by a dysfunctional fasting blood glucose that reaches 7.0 mmol/L or higher, and insulin resistance caused by hyperglycemia.
The number affected is increasing rapidly with alarming trends in children and young adults (up to age 40 years). In 2021, it is estimated that 537 million people have diabetes mellitus, and this number is projected to reach 783 million by 2045.
Long-term hyperglycemia will continue to harm the health of diabetic patients, bringing various complications, including retinopathy, kidney disease, neuropathy, macrovascular disease, cardiomyopathy, infection, metabolic dysfunction, etc.
P37, a group of legume-derived 37-amino-acid polypeptides, resists gastrointestinal protease degradation. They exhibits excellent orally hypoglycemic activity and can repair the dysfunctional pancreas. Through the prediction of the model, we screened the member Vglycin that has higher activity and affinity to its receptor.
At present, Vglycin can only be extracted from soybeans, which has problems such as low yield, complex process, and waste of land resources. Therefore, in order to benefit more people from Vglycin related treatments in the future, we plan to use synthetic biology methods to construct a Vglycin expression system.
Our biomanufacturing system aims to make Vglycin easily accessible and allow for further exploration of Vglycin based treatment methods.
